Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation by Schoots, I.G. (Ivo) & Padhani, A. (Anwar)
Risk-adapted biopsy decision based on prostate
magnetic resonance imaging and prostate-specific
antigen density for enhanced biopsy avoidance in first
prostate cancer diagnostic evaluation
Prostate MRI has been integrated into the diagnostic
evaluation for men at risk of having clinically significant
cancer in multiple clinical care guidelines. Owing to the low
false-negative rate of prostate MRI accompanying a sensitivity
averaging 91%, we can reduce biopsies (by 30%) and indolent
cancer detection, while maintaining (or even improving)
detection of significant cancers compared to systematic biopsy
[1]. Reducing false-negative MRI results further remains a
clinical priority, calling for risk-adapted strategies for patient
biopsy selection [2,3]. Multivariable risk-prediction tools
incorporating MRI results have been developed [4], but
remain unvalidated.
Multiple publications advise the combination of MRI findings
and PSA density (PSAD) for defining men who can safely
avoid biopsy [5,6]. In the present analysis, we extract in
biopsy-na€ıve men, the data relating to prostate MRI results
and PSAD values to the likelihood of clinically significant
disease. We propose a simple, risk-adapted advice for biopsy
avoidance, based on current urological guideline thresholds.
Our analyses are meant to be hypothesis generating, requiring
prospective validation.
Using PubMed/Ovid-MEDLINE literature searches (up to
May 2020), studies on biopsy-na€ıve men undergoing
systematic and where indicated MRI-directed targeted
biopsies at the same time, that provided three or four PSAD
risk categories in the low-, intermediate- and high-risk range
were found and related to Prostate Imaging-Reporting and
Data System (PI-RADS) scores [5–9]. Studies using a single
threshold for PSAD or binary MRI classification (positive/
negative) were excluded, as were multivariate studies using
PSADs. We also excluded studies that only included selected
negative or equivocal MRI studies without prevalence data.
In total, 3006 biopsy-na€ıve men in five studies were included
(study characteristics Table S1). The overall prevalence of
significant disease (International Society of Urological
Pathology [ISUP] ≥2 cancers) among studies was 39% (range
28–49%).
The population was stratified into four (or three; rates
between brackets) PSAD risk groups (Table 1 [5–10): <0.10,
0.10–0.15, 0.15–0.20, and >0.20 ng/mL/mL, corresponding to
31% (29%), 28%, 16%, and 25% (27%) of the whole
population; with ISUP ≥2 cancer detection rates of 11%
(14%), 28%, 47%, and 66% (68%), respectively.
The population was also stratified into three PI-RADS
category risk groups: PI-RADS 1–2 (low risk), 3 (intermediate
risk ), and 4–5 (high risk), corresponding to 38% (36%), 12%
(14%), and 50% (51%) of whole study population, with ISUP
≥2 detection rates of 6% (9%), 16% (22%), and 62% (65%),
respectively (Table 1).
MRI-negative men (PI-RADS 1–2) with a low-risk PSAD
(<0.10 ng/mL/mL) have a 3% (4%) risk of significant disease
(Table 1, Fig. S1a). MRI-negative men with intermediate–low
(0.10–0.15 ng/mL/mL) or intermediate–high risk PSAD
(0.15–0.20 ng/mL/mL) have respectively 7% and 8% risk of
significant disease. MRI-negative men with a high-risk PSAD
(>0.20 ng/mL/mL) have 18% (24%) risk of significant disease.
These data suggest that MRI-negative men with low-risk
PSADs can avoid biopsies all together (lower than average
population risk [<5%] [10]). Additionally, using the European
Association of Urology (EAU)/National Institute for Health
and Care Excellence (NICE)/AUA recommendations, MRI-
negative men with a PSAD of 0.10–0.15 or 0.15–0.20 ng/mL/
mL may avoid immediate biopsy with an adequate safety-net
of monitoring as part of shared decision-making. However,
MRI-negative men with a high-risk PSAD (>0.20 ng/mL/mL)
require systemic biopsies, despite the absence of visible MRI-
targets (Fig. S1a).
Men with indeterminate PI-RADS 3 scores and a low-risk
PSAD (<0.10 ng/mL/mL) have a low 4% (9%) risk of
significant disease, and biopsies could be avoided
(Table 1, Fig. S1a). Men with PI-RADS 3 scores and a
high-risk PSAD (>0.20 ng/mL/mL) have an elevated 29%
(36%) risk, and targeted and systematic biopsies should
be taken.
MRI-positive men with PI-RADS 4–5 category scores,
irrespective of PSAD-risk categories, should undergo targeted
with or without systematic biopsies (EAU recommendations).
Indeed, PI-RADS 4–5 category scores were found in 189 of
674 (28%) men with low-risk PSAD values (<0.10 ng/mL/
mL); in these men, 31% were found to have significant
disease, indicating that biopsies should be taken in men with
low PSAD values when MRI scans are positive.
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When only considering biopsy at a PSAD of >0.10 ng/mL/
mL (without MRI assessments), 31% (28%) of biopsies are
avoided at the expense of missing significant disease in 9%
(10%) in whole tested population (Table S2). On the other
hand, taking the combination of PI-RADS scores with PSAD
risk categories described above for biopsy decisions, a total of
38% (36%) biopsies can be avoided at the lower expense of
missing significant cancers in 5% (6%) (Table S2).
Overall, a PSAD of >0.20 ng/mL/mL impacts 68 of 839 (8%)
MRI-negative men by increasing biopsy procedures (Table 1).
A PSAD of <0.10 ng/mL/mL impacts 74 of 254 (29%)
Table 1 Risk data table of clinically significant prostate cancer (csPCa), related to PI-RADS score and PSAD categories in biopsy-na€ıve men, clinically
suspected of having significant disease.
Study PI-RADS risk 
categories
Prevalence





high PI-RADS risk 
categories
Prevalence
ISUP ≥ 2 PCa
low intermediate high
< 0.10 0.10 - 0.15 0.15 - 0.20 ≥ 0.20 < 0.10 0.10 - 0.20 ≥ 0.20
31% 28% 16% 25% 28% 45% 27%
(678/2199) (612/2199) (360/2199) (553/2199) (851/3006) (1357/3006) (798/3006)
Boesen (2019) PI-RADS 1-2 7% (21/300) 3% (4/139) 7% (7/102) 8% (3/37) 32% (7/22) PI-RADS 1-2 7% (21/300) 3% (4/139) 7% (10/139) 32% (7/22)
Knaapila (2019) 38% 7% (8/113) 6% (2/32) 8% (3/40) 9% (2/22) 5% (1/19) 36% 7% (8/113) 6% (2/36) 8% (5/62) 5% (1/19)
Van der Leest (2019) (839/2199) 3% (10/309) 2% (4/165) 3% (3/89) 5% (2/39) 6% (1/16) (1075/3006) 3% (10/309) 2% (4/165) 4% (5/128) 6% (1/16)
Falagario (2019) 8% (9/117) 2% (1/75) 16% (4/25) 17% (1/6) 27% (3/11) 8% (9/117) 2% (1/75) 16% (5/31) 27% (3/11)
Hansen (2018) 20% (48/236) 9% (6/66) 21% (26/122) 33% (16/48)
Boesen (2019) PI-RADS 3 19% (23/124) 6% (3/48) 8% (3/40) 53% (9/17) 42% (8/19) PI-RADS 3 19% (23/124) 6% (3/48) 21% (12/57) 42% (8/19)
Knaapila (2019) 12% 10% (9/90) 0% (0/14) 13% (4/31) 5% (1/19) 15% (4/26) 14% 10% (9/90) 0% (0/14) 10% (5/50) 15% (4/26)
Van der Leest (2019) (254/2199) 23% (9/40) 0% (0/12) 24% (4/17) 40% (2/5) 50% (3/6) (407/3006) 23% (9/40) 0% (0/12) 27% (6/22) 50% (3/6)
Hansen (2018) 31% (47/153) 18% (7/38) 31% (28/90) 48% (12/25)
Boesen (2019) PI-RADS 4-5 62% (239/384) 35% (18/52) 52% (60/115) 65% (53/81) 79% (108/136) PI-RADS 4-5 62% (239/384) 35% (18/52) 58% (113/196) 79% (108/136)
Knaapila (2019) 50% 72% (212/296) 50% (14/28) 64% (27/42) 72% (48/67) 77% (123/159) 51% 72% (212/296) 50% (14/28) 69% (75/109) 77% (123/159)
Van der Leest (2019) (1106/2199) 62% (171/277) 36% (20/56) 58% (42/73) 71% (34/48) 75% (75/100) (1524/3006) 62% (171/277) 36% (20/56) 63% (76/121) 75% (75/100)
Falagario (2019) *44% (65/149) *13% (7/53) *39% (15/38) *68% (13/19) *77% (30/39) *44% (65/149) *13% (7/53) *49% (28/57) *77% (30/39)
Hansen (2018) 71% (297/418) 48% (35/73) 66% (114/173) 86% (148/172)
Compiled totals of csPCa risk
6% 3% 7% 8% 18% 9% 4% 11% 24%
(48/839) (11/411) (17/256) (8/104)  (12/68) (96/1075) (17/477) (51/482) (28/116)
16% 4% 13% 29% 29% 22% 9% 23% 36%
(41/254) (3/74) (11/88) (12/41) (15/51) (88/407) (10/112) (51/219) (27/76)
62% 31% 54% 69% 77% 65% 36% 62% 80%
(687/1106) (59/189) (144/268) (148/215) (336/434) (984/1524) (94/262) (406/656) (484/606)
All PI-RADS 35% 11% 28% 47% 66% All PI-RADS 39% 14% 37% 68%
(776/2199) (73/674) (172/612) (168/360) (363/553) (1168/3006) (121/851) (508/1357) (539/798)
Risk-adapted matrix table for biopsy decision management
very low 0-5% csPCa (below population risk) # # Thompson IM et al. N Engl J Med. 2004 May 27;350(22):2239-46. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng/ml.
low 5-10% csPCa (acceptable risk) ## ## 2019 EAU PCa guidelines: csPCa 9% (95%CI: 6-14%)
intermediate-low 10-20% csPCa = accepted risk (MRI sensitivity of 91% (95%CI: 83-95%) and NPV 91% (95%CI:86-94%), at a prevalence of 29% (95%CI:22-38%))
intermediate-high 20-30% csPCa
high 30-40% csPCa * PI-RADS 3-5 instead of PI-RADS 4-5 category, as this data was not reported, slightly underestimating the actual numbers.
very high >40% csPCa PSA: prostate specific antigen; PI-RADS: prostate imaging reporting and data system; csPCa: clinically significant prostate cancer; ISUP: international Society of Urogenital Pathology grading.
 (ng/ml/cm3)  (ng/ml/cm3)
Detection of clinically significant prostate cancer (ISUP grade 2 and higher) 
PSA-density risk groups PSA-density risk groups
4 categories 3 categories
PI-RADS 1-2 PI-RADS 1-2
PI-RADS 3  PI-RADS 3  















PI-RADS 3  no biopsy


























© 2020 The Authors
BJU International
Schoots and Padhani
PI-RADS 3 category men who could avoid biopsies. PSAD
does not impact biopsy decisions in PI-RADS 4–5 category
men. Therefore, in the combined risk strategy of MRI with
PSAD thresholds proposed above, the total number of men
avoiding biopsies (38%) is unchanged compared to using only
MRI risk assessment (38%), but men are more appropriately
selected according to individual risk (Fig. S1a).
This analysis has limitations that require careful
consideration. We have categorised biopsy-na€ıve men into
different risk profiles based on their MRI risk categories and
PSAD ranges. We are cognisant that categorisation of
continuous variables such as PSAD values is not advisable
statistically for creating risk-prediction models, due to the loss
of information and power. However, we are not creating a
model for biopsy avoidance; instead, we are merely
confirming the potential for clinically meaningful inferences
as noted by Boesen et al. [5] and Falagario et al. [6]. Further,
justification of PSAD categories comes from their common
usage in clinical care guidelines (EAU, NICE) making our
present findings practically relevant (Fig. 1). We recognise
that some data points have small numbers of patients making
the estimates of the risk of significant cancers less reliable.
We also recognise that these data are applicable for a mean
ISUP ≥2 prevalence of 35% (range 28–46%) in biopsy-na€ıve
men, and would need to be adjusted to other population
prevalence’s. Validation of our approach of adapting MRI
findings by PSAD values for biopsy decisions is beginning to
emerge [11] (Fig. S1b), reinforcing their routine use for
biopsy decisions in clinical practice (EAU, NICE), while we
wait the validation of MRI-based multivariate risk prediction
tools. The proposed approach is hypothesis generating and in
need of further prospective validation in different populations
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Fig. 1 Risk-adapted matrix table for guidance in biopsy decision, based on PSAD and on MRI risk assessments. The continuum of estimated risks of
having a biopsy-detectable prostate cancer are categorised into low- (not elevated), intermediate- and high-risk (elevated). Generally, men at higher
risk of having clinically significant prostate cancer require biopsy regardless of how risk is estimated. The MRI risk assessment is categorised into low (PI-
RADS 1 or 2), intermediate (PI-RADS 3) or high (PI-RADS 4–5) risk of having a biopsy-detectable clinically significant prostate cancer. Each cell ascribes a
different biopsy action, based on the results of Table 1. This matrix table may help guide biopsy-decision management, while awaiting the validation of
multivariable MRI prediction tools.
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Additional Supporting Information may be found in the
online version of this article:
Table S1. Study characteristics.
Table S2. Diagnostics metrics for significant prostate cancer
detection (ISUP Grade ≥2) at various thresholds of PI-RADS
score and PSAD risk category, related to biopsy avoidance.
Fig. S1. Proportions of clinically significant prostate cancer
related to PI-RADS and PSAD risk category in biopsy-na€ıve
men.
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